Literature DB >> 30841835

The Superior Cavopulmonary Connection: History and Current Perspectives.

Jeremy L Herrmann1,2, John W Brown1,2.   

Abstract

The development of the superior cavopulmonary connection is a rich illustration of international influences in congenital cardiac surgery. The bidirectional Glenn and hemi-Fontan procedures have improved survival as both definitive and staged functional single ventricle palliation. The optimal timing of the second-stage superior cavopulmonary procedures varies by center but for low- and intermediate-risk patients, this may be within three to six months after the Norwood procedure. The list of risk factors continues to grow but the most frequently cited factors include atrioventricular valve regurgitation, decreased ventricular function, need for reintervention, and failure to attain nutritional and growth goals. Ongoing prospective, multi-institutional studies, particularly those fostered internationally by the World Society for Pediatric and Congenital Heart Surgery and other associations, will hopefully provide further clarification of the complex management issues related to patients with functional single ventricle physiology.

Entities:  

Keywords:  cavopulmonary anastomosis; congenital heart surgery; hypoplastic left heart syndrome; palliation

Mesh:

Year:  2019        PMID: 30841835     DOI: 10.1177/2150135119825560

Source DB:  PubMed          Journal:  World J Pediatr Congenit Heart Surg        ISSN: 2150-1351


  2 in total

1.  Surgical Timing and Outcomes of Unilateral Versus Bilateral Superior Cavopulmonary Anastomosis: An Analysis of Pediatric Heart Network Public Databases.

Authors:  Jeffrey M Shuler; Chris Statile; Haleh Heydarian; David G Lehenbauer; Garick D Hill
Journal:  Pediatr Cardiol       Date:  2021-01-08       Impact factor: 1.655

2.  Loss of Ventricular Function After Bidirectional Cavopulmonary Connection: Who Is at Risk?

Authors:  Marie Vincenti; M Yasir Qureshi; Talha Niaz; Drew K Seisler; Timothy J Nelson; Frank Cetta
Journal:  Pediatr Cardiol       Date:  2020-08-11       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.